Only one of these two pharma titans has a history of growth.
News & Analysis: Merck & Co.
The company has raised its dividend payments by more than 35% over the past five years.
These two healthcare companies have more than their COVID-19 programs going for them.
The White House reportedly plans to route extra federal funds and other assistance to the companies developing those potential SARS-CoV-2 vaccines.
Spending on pet health continues to climb. Investors should consider buying PetMed Express, Phibro Animal Health, and Merck & Co.
The blockbuster cancer treatment delivered strong results in another clinical trial.
If you've got some savings built up, this can be an easy way to supplement your income.
These drug developers will give your portfolio a boost.
The big pharma has finally joined its peers, launching multiple projects aimed at stopping COVID-19 in its tracks.
Merck is going after COVID-19 from multiple angles, and McDonald's should benefit from rising restaurant visits.